{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:34:07Z","timestamp":1788910447288,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["68388"],"award-info":[{"award-number":["68388"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bipolar disorder type I is defined by the occurrence of at least one manic episode, presenting with elevated mood, hyperactivity, and restlessness. Effective management relies primarily on pharmacotherapy, with lithium carbonate and quetiapine proven beneficial as monotherapies. Given the chronic nature of the illness and alternating manic\u2013depressive phases, acute mania requires rapid symptom control to prevent functional decline and harm. Although lithium is a cornerstone mood stabilizer, its clinical effect may take days to emerge. Quetiapine, an atypical antipsychotic, provides faster relief in acute mania. Evidence suggests that combining these agents may offer superior control of manic symptoms compared to either drug alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to compare the efficacy of a lithium carbonate loading dose combined with quetiapine against the standard lithium carbonate dosage alongside quetiapine for managing acute mania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This interventional randomized clinical trial (IRCT20181204041847N2) was a prospectively designed, retrospectively registered study conducted at a psychiatric hospital and conducted on 60 adult inpatients diagnosed with Bipolar I disorder in the acute manic phase, according to DSM-5 criteria and a Young Mania Rating Scale (YMRS) score of \u2265\u200920. Participants were equally allocated to two arms using block randomization. The loading-dose lithium group received a loading dose of lithium carbonate on Day 1 at 20\u00a0mg\/kg (maximum 1,800\u00a0mg), followed by standard dosing from Day 2 onward. The standard-dose lithium group received lithium carbonate starting at 300\u00a0mg\/day, increased in 300\u00a0mg increments every 2\u20133 days until reaching 900\u20131,200\u00a0mg\/day, with serum concentrations consistently maintained within 0.6\u20131.2 mEq\/L. Quetiapine was initiated at 100\u00a0mg\/day in two divided doses and titrated by 100\u2013200\u00a0mg\/day increments to a target of 400\u2013800\u00a0mg\/day based on clinical response and tolerability. Mania severity was assessed using the YMRS at baseline and on Days 3, 7, and 14 after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study of 60 patients with acute mania, both treatment groups showed significant reductions in YMRS scores over 14 days (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The loading dose group achieved a greater mean decrease from baseline (\u2212\u200917.70\u2009\u00b1\u20093.76) compared with the standard dose group (\u2212\u200913.96\u2009\u00b1\u20092.94;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Lithium serum levels reached therapeutic ranges sooner in the loading group (Day 5: 0.82\u2009\u00b1\u20090.11 mEq\/L vs. 0.65\u2009\u00b1\u20090.13; Day 10: 0.78\u2009\u00b1\u20090.09 vs. 0.68\u2009\u00b1\u20090.10). Aggressive\/disruptive behavior scores were also lower in the loading group by Day 14 (0.36\u2009\u00b1\u20090.06 vs. 0.89\u2009\u00b1\u20090.53;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). The incidence of common adverse events was comparable, and no cases exceeded lithium serum levels of 1.4 mEq\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study found that adding a lithium loading dose to quetiapine significantly enhanced the reduction of acute mania symptoms compared with standard dosing, without increasing short-term adverse events. These results support the regimen\u2019s clinical benefit, though confirmation through larger, long-term trials is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>IRCT20181204041847N2; Registration Date: 16 August 2023; No: 68,388.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-08084-z","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:25:05Z","timestamp":1776799505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of lithium carbonate loading dose versus standard dosing, each combined with quetiapine, in acute mania of bipolar I disorder: a randomized single-blind controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Ebrahim","family":"Moghimi-Sarani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Zahra","family":"Etemad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raziye","family":"Dehbozorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"2","key":"8084_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1399-5618.2004.00180.x","volume":"7","author":"ADDINENREFLIST Kawa","year":"2005","unstructured":"Kawa ADDINENREFLIST, Carter I, Joyce JD, Doughty PR, Frampton CJ, Elisabeth Wells CM. Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord. 2005;7(2):119\u201325.","journal-title":"Bipolar Disord"},{"issue":"10027","key":"8084_CR2","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","volume":"387","author":"I Grande","year":"2016","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561\u201372.","journal-title":"Lancet"},{"issue":"2","key":"8084_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170.","journal-title":"Bipolar Disord"},{"key":"8084_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jad.2017.03.052","volume":"217","author":"GS Malhi","year":"2017","unstructured":"Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord. 2017;217:266\u201380.","journal-title":"J Affect Disord"},{"issue":"9817","key":"8084_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","volume":"379","author":"RF McKnight","year":"2012","unstructured":"McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721\u20138.","journal-title":"Lancet"},{"issue":"7","key":"8084_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1089\/cap.2021.0039","volume":"31","author":"LR Patino","year":"2021","unstructured":"Patino LR, Klein CC, Strawn JR, Blom TJ, Tallman MJ, Adler CM, et al. A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder. J Child Adolesc Psychopharmacol. 2021;31(7):485\u201393.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"8084_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","volume":"109","author":"E Vieta","year":"2008","unstructured":"Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109(3):251\u201363.","journal-title":"J Affect Disord"},{"issue":"2","key":"8084_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/acps.13062","volume":"140","author":"T Hui","year":"2019","unstructured":"Hui T, Kandola A, Shen L, Lewis G, Osborn D, Geddes J, et al. A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta psychiatrica Scandinavica. 2019;140(2):94\u2013115.","journal-title":"Acta psychiatrica Scandinavica"},{"issue":"1","key":"8084_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4088\/JCP.14m09349","volume":"77","author":"AA Nierenberg","year":"2016","unstructured":"Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, et al. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016;77(1):90\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"8084_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bdi.12027","volume":"15","author":"WA Nolen","year":"2013","unstructured":"Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord. 2013;15(1):100\u20139.","journal-title":"Bipolar Disord"},{"key":"8084_CR11","doi-asserted-by":"crossref","unstructured":"McKnight RF, Chesney E, Amit BH, Geddes J, Cipriani A. Lithium for acute mania. Cochrane database Syst reviews. 2019(6).","DOI":"10.1002\/14651858.CD004048.pub4"},{"issue":"6","key":"8084_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1185\/030079905X46340","volume":"21","author":"E Vieta","year":"2005","unstructured":"Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21(6):923\u201334.","journal-title":"Curr Med Res Opin"},{"key":"8084_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jad.2015.11.002","volume":"191","author":"TA Ketter","year":"2016","unstructured":"Ketter TA, Miller S, Dell\u2019Osso B, Wang PW. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256\u201373.","journal-title":"J Affect Disord"},{"key":"8084_CR14","doi-asserted-by":"crossref","unstructured":"Bauer M, Gitlin M. The essential guide to lithium treatment. Springer; 2016.","DOI":"10.1007\/978-3-319-31214-9"},{"issue":"5","key":"8084_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bdi.12752","volume":"21","author":"TT Kim","year":"2019","unstructured":"Kim TT, Dufour S, Xu C, Cohen ZD, Sylvia L, Deckersbach T, et al. Predictive modeling for response to lithium and quetiapine in bipolar disorder. Bipolar Disord. 2019;21(5):428\u201336.","journal-title":"Bipolar Disord"},{"issue":"9878","key":"8084_CR16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","volume":"381","author":"JR Geddes","year":"2013","unstructured":"Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. lancet. 2013;381(9878):1672\u201382.","journal-title":"lancet"},{"issue":"5","key":"8084_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1399-5618.2009.00726.x","volume":"11","author":"M Tohen","year":"2009","unstructured":"Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453\u201373.","journal-title":"Bipolar Disord"},{"issue":"7","key":"8084_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bdi.12556","volume":"19","author":"BI Goldstein","year":"2017","unstructured":"Goldstein BI, Birmaher B, Carlson GA, DelBello MP, Findling RL, Fristad M, et al. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disord. 2017;19(7):524\u201343.","journal-title":"Bipolar Disord"},{"issue":"6","key":"8084_CR19","first-page":"7517","volume":"76","author":"TY n der Voort","year":"2015","unstructured":"Van der Voort TY, Seldenrijk A, van Meijel B, Goossens PJ, Beekman AT, Penninx BW, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015;76(6):7517.","journal-title":"J Clin Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08084-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08084-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:02Z","timestamp":1781649062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08084-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8084"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08084-z","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethics approval from the Institutional Review Board of Shiraz University of Medical Sciences (Approval Number: IR.SUMS.MED.REC.1401.530), and all procedures were conducted in accordance with relevant guidelines and regulations, as outlined in the Declaration of Helsinki. Prior to enrollment, all participants were provided with a detailed explanation of the study objectives, procedures, potential risks, and anticipated benefits. Participant confidentiality was strictly maintained, with all data securely stored and accessible only to authorized members of the research team. Identifiable information was coded to protect privacy, and all findings are reported in aggregate form to prevent disclosure of individual identities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written and verbal informed consent was obtained from each participant, ensuring voluntary participation and the right to withdraw at any stage without any impact on their standard medical care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"444"}}